2-bromo-4-chlorobenzylchloride | 66192-23-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-bromo-4-chlorobenzylchloride
• 英文别名: 2-Bromo-4-chloro-1-(chloromethyl)benzene
• CAS: 66192-23-2
• 化学式: C₇H₅BrCl₂
• 分子量: 239.927
• InChiKey: SNPYGOQMBFNDLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  2-bromo-4-chlorobenzylchloride 在 四(三苯基膦)钯 、 potassium carbonate 、 potassium iodide 作用下， 以 水 、 丙酮 、 乙腈 为溶剂， 反应 32.0h， 生成 methyl 3-(4-((5-chloro-[1,1'-biphenyl]-2-yl)methoxy)phenyl)propanoate
  参考文献：
  名称：

  Discovery of a Potent and Selective GPR120 Agonist

  摘要：

  GPR120 is a receptor of unsaturated long-chain fatty acids reported to mediate GLP-1 secretion, insulin sensitization, anti-inflammatory, and anti-obesity effects and is therefore emerging as a new potential target for treatment of type 2 diabetes and metabolic diseases. Further investigation is however hindered by the lack of suitable receptor modulators. Screening of FFA1 ligands provided a lead with moderate activity on GPR120 and moderate selectivity over FFA1. Optimization led to the discovery of the first potent and selective GPR120 agonist.

  DOI：

  10.1021/jm300215x
• 作为产物：
  描述：

  2-溴-4-氯苯甲醛 在 甲醇 、 sodium tetrahydroborate 、 氯化亚砜 作用下， 反应 3.5h， 生成 2-bromo-4-chlorobenzylchloride
  参考文献：
  名称：

  [EN] α1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE
  [FR] AGONISTES DU RÉCEPTEUR α1A-ADRÉNERGIQUE ET MÉTHODES D'UTILISATION

  摘要：

  本公开涉及化合物，某些实施例涉及α1A-肾上腺素能受体激动剂以及这些激动剂在治疗与肾上腺素能受体相关的疾病中的用途。本文披露了一种按照公式（I）或其光学纯立体异构体，药物可接受的盐，溶剂或前药的化合物。

  公开号：

  WO2022047052A1

文献信息

• Nickel-Catalyzed Chemo- and Regioselective Benzylarylation of Unactivated Alkenes with <i>o</i>-Bromobenzyl Chlorides
  作者：Hailong Wang、Haichao Huang、Chao Gong、Yong Diao、Jianmei Chen、Si-Hai Wu、Lianhui Wang

  DOI：10.1021/acs.orglett.1c03991

  日期：2022.1.14

  Chemo- and regioselectively nickel-catalyzed reductive benzylarylation of unactivated alkenes with o-bromobenzyl chlorides is disclosed herein, in which electrophiles participate through a single-component double-site approach. Moreover, its utility is underscored by the concise synthesis of bioactive Indane compounds and postreaction functionalizations leading to structurally diverse scaffolds. Preliminary

  本文公开了化学和区域选择性镍催化的未活化烯烃与邻溴苄基氯的还原苄基化反应，其中亲电试剂通过单组分双位点方法参与。此外，生物活性茚满化合物的简明合成和导致结构多样化的支架的反应后功能化强调了它的实用性。初步的机理研究表明存在自由基链式反应机制。
• Discovery of a Potent and Selective GPR120 Agonist
  作者：Bharat Shimpukade、Brian D. Hudson、Christine Kiel Hovgaard、Graeme Milligan、Trond Ulven

  DOI：10.1021/jm300215x

  日期：2012.5.10

  GPR120 is a receptor of unsaturated long-chain fatty acids reported to mediate GLP-1 secretion, insulin sensitization, anti-inflammatory, and anti-obesity effects and is therefore emerging as a new potential target for treatment of type 2 diabetes and metabolic diseases. Further investigation is however hindered by the lack of suitable receptor modulators. Screening of FFA1 ligands provided a lead with moderate activity on GPR120 and moderate selectivity over FFA1. Optimization led to the discovery of the first potent and selective GPR120 agonist.
• [EN] α1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE<br/>[FR] AGONISTES DU RÉCEPTEUR α1A-ADRÉNERGIQUE ET MÉTHODES D'UTILISATION
  申请人：CURASEN THERAPEUTICS INC

  公开号：WO2022047052A1

  公开（公告）日：2022-03-03

  The present disclosure relates generally to chemical compounds and, in some embodiments, to α1A-adrenergic receptor agonists and uses of such agonists in the treatment of diseases associated with an adrenergic receptor. Disclosed herein is a compound according to Formula (I) or an optically pure stereoisomer, pharmaceutically acceptable salt, solvate, or prodrug thereof.

  本公开涉及化合物，某些实施例涉及α1A-肾上腺素能受体激动剂以及这些激动剂在治疗与肾上腺素能受体相关的疾病中的用途。本文披露了一种按照公式（I）或其光学纯立体异构体，药物可接受的盐，溶剂或前药的化合物。